$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Controlled release formulations coated with aqueous dispersions of acrylic polymers 원문보기

IPC분류정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판)
  • A61K-009/62
출원번호 US-0459110 (1995-06-02)
발명자 / 주소
  • Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi
  • Jr. Frank (Yorktown Heights NY)
출원인 / 주소
  • Euro-Celtique, S.A. (LUX 03)
인용정보 피인용 횟수 : 696  인용 특허 : 39

초록

A stable solid controlled release formulation having a coating derived from an aqueous dispersion of a hydrophobic acrylic polymer includes a substrate including an active agent selected from the group consisting of a systemically active therapeutic agent, a locally active therapeutic agent, a disin

대표청구항

A controlled release dosage form, comprising a substrate containing an active agent in an amount sufficient to provide a desired effect, said substrate being coated with a plasticized aqueous dispersion consisting essentially of ammonio-methacrylate copolymers which are copolymerizates of acrylic ac

이 특허에 인용된 특허 (39)

  1. Miura Yuzo (Nishinomiya JPX) Ohnishi Masanobu (Osaka JPX) Mabuchi Tsutomu (Kawachinagano JPX) Yanai Isao (Osakasayama JPX), 3-(substituted phenyl) pyrazole derivatives herbicidal composition containing the same and method of controlling weeds u.
  2. Edgren David E. (El Granada CA) Theeuwes Felix (Los Altos CA), Annealed coats.
  3. Wong Patrick S. L. (Hayward CA) Theeuwes Felix (Los Altos CA), Aqueous emulsion for pharmaceutical dosage form.
  4. Belanger Raymond J. (Rensselaer NY) Stetsko Gregg (Bethlehem NY) Pagay Shrikant N. (Guilderland NY), Aqueous spray-coating process.
  5. Abramowitz Robert (Somerset NJ) Joshi Yatinda M. (Piscataway NJ) Jain Nemichand B. (Monmouth Junction NJ), Captopril formulation providing increased duration of activity.
  6. Ventouras Kimon (Le Lignon CHX), Controlled release tablet.
  7. Mueller, Karl F.; Heiber, Sonia J., Crosslinked, porous polymers for controlled drug delivery.
  8. Geoghegan Edward J. (Athlone IEX) Mulligan Seamus (Athlone IEX) Panoz Donald E. (Tuckerstown BMX), Diltiazem formulation.
  9. Wright Jeremy C. (Los Altos CA) Guittard George V. (Cupertino CA), Dosage form for delivering drug to the intestine.
  10. Wirth Dagmar (Magden CHX) Bucher Christian (Freiburg DEX), Double-coated granules of disodium pamidronate.
  11. Paradissis George N. (St. Louis MO) Garegnani James A. (Ballwin MO) Whaley Roy S. (St. Louis MO), Extended release pharmaceutical formulations.
  12. Ventouras Kimon (Le Lignon CHX), Granular delayed-release form of pharmaceutically active substances.
  13. Lehmann Klaus (Rossdorf DEX) Dreher Dieter (Darmstadt DEX) Rauch Hubert (Weiterstadt DEX) Siol Werner (Pfungstadt DEX), Method for coating medicaments.
  14. Lehmann Klaus (Rossdorf DEX) Dreher Dieter (Darmstadt DEX) Goetz Harry (Alsbach-Haehnlein DEX), Method for coating pharmaceutical formulations.
  15. Iwanami Koichi (Yokohama JPX) Ito Masatsugu (Tokyo JPX), Method for producing organic agent coated with powders of coating agent.
  16. Fontanelli Luciano (Pisa ITX), Method for the preparation of granulates suited for the production of sustained release coated tablets for oral use.
  17. Samejima Masayoshi (Minoh JPX) Hirata Goichi (Yawata JPX), Method of preparing microcapsules.
  18. Cowsar Donald R. (Birmingham AL) Dunn Richard L. (Fort Collins CO) Laughlin Thomas J. (Germantown TN), Method of producing zero-order controlled-released devices.
  19. Michaelis ; Arthur F., Methods for the preparation of controlled gastric residence time medicament formulations.
  20. Geoghegan Edward J. (Athlone GA IEX) Mulligan Seamus (Gainesville GA) Panoz Donald E. (Tuckerstown BMX), Methods of treatment with diltiazem formulations.
  21. Valenti Mauro (Magenta ITX), Microencapsulation of a medicament.
  22. Iamartino Piero (Monza ITX) Maffione Grazia (Milan ITX) Pontello Lino (Milan ITX), Orally-pharmaceutical preparations with colon selective delivery.
  23. Imondi Anthony R. (Westerville OH) Hagerman Larry M. (Columbus OH), Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane.
  24. Jones Harry P. (Dartford GB2) Mackey Robert J. (Dartford GB2) Gamlen Michael J. D. (Dartford GB2), Pharmaceutical formulations containing acrivastine.
  25. Lovgren Kurt I. (Mlnlycke SEX) Pilbrant Ake G. (Kungsbacka SEX) Yasumura Mitsuru (Hyogo JPX) Morigaki Satoshi (Hyogo JPX) Oda Minoru (Ohita JPX) Ohishi Naohiro (Fukuoka JPX), Pharmaceutical formulations of acid labile substances for oral use.
  26. Lovgren Kurt I. (Mlnlycke SEX) Pilbrant Ake G. (Kungsbacka SEX) Yasumura Mitsuru (Hyogo JPX) Morigaki Satoshi (Hyogo JPX) Oda Minoru (Ohita JPX) Ohishi Naohiro (Fukuoka JPX), Pharmaceutical preparation for oral use.
  27. Chen Li J. (Hsin-Ying) Chen Chun N. (Chia-Yi) Lin Shan Y. (Taipei TWX), Preparation method of microdispersed tablet formulation of spray-dried sodium diclofenac enteric-coated microcapsules.
  28. Groppenbacher Gregor (Mannheim-Feudenheim DT) Rieckmann Peter (Mannheim-Waldhof DT) Rothe Werner (Hockenheim DT), Process for coating tablets with aqueous resin dispersions.
  29. Prud\Homme Christian (Lyons FRX) Porte Hugues (Caluire FRX), Process for encapsulating particles with a silicone.
  30. Ghebre-Sellassie Isaac (Randolph NJ) Gordon Robert H. (Dover NJ) Harris Michael R. (Budd Lake NJ) Nesbitt ; Jr. Russell U. (Somerville NJ), Process for treating dosage forms.
  31. Wu Stephen H. W. (Kingsport TN) Kirk Shane K. (Church Hill TN) Perry Kenneth P. (Kingsport TN) Smith E. Phillip (Blountville TN) Chang Yeong-Ho (Kingsport TN) Jenkins Waylon L. (Kingsport TN), Rumen-stable pellets.
  32. Khanna Satish C. (Bottmingen CHX), Solid, stable dosage forms with an elastic film coating.
  33. Fawzi Mahdi B. (Flanders NJ) Kubert Daniel A. (Lafayette NJ) Murthy Kuchi S. (Morris Plains NJ), Stabilization of enteric coated dosage form.
  34. Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Stabilized controlled release formulations having acrylic polymer coating.
  35. Morella Angelo M. (Campbelltown AUX) Fisher Mark C. (Birkenhead AUX), Sustained release pharmaceutical composition.
  36. Stevens Howard (Grande-Bretagne GB6) Chariot Maryvonne (Maisons-Alfort NJ FRX) Arnold Francoise (Plainsboro NJ) Lewis Gareth (Dourdan FRX), Sustained release pharmaceutical composition of diltiazem.
  37. Mazer Terrence B. (Reynoldsburg OH) Meyer Glenn A. (Wankegan IL) Hwang Shie-Ming (Arlington OH) Candler ; Jr. Edrick L. (Dublin OH) Drayer Lonnie R. (Gahanna OH) Daab-Krzykowski Andre (Columbus OH), System for delivering an active substance for sustained release.
  38. Groppenbacher Gregor (Mannheim-Feudenheim DT) Rieckmann Peter (Mannheim-Waldhof DT) Rothe Werner (Hockenheim DT), Tablets coated with aqueous resin dispersions.
  39. Mehta Atul M. (Ramsey NJ), Taste-masked pharmaceutical compositions.

이 특허를 인용한 특허 (696)

  1. Reisch, Helge A., 1,3-dioxanomorphides and 1,3-dioxanocodides.
  2. Brown, Kevin C.; Goehring, R. Richard, 2,3,4,5-tetrahydro-benzo{B}{1,4}diazepine-comprising compounds of formula(III) for treating pain.
  3. Sun, Lijun; Chen, Shoujun; Jiang, Jun; Xie, Yu; Yu, Chih-Yi, 2-amido pyrazines for inflammation and immune related uses.
  4. Ly, Tai Wei, 3,5-diaminopyrazole kinase inhibitors.
  5. Ly, Tai Wei, 3,5-diaminopyrazole kinase inhibitors.
  6. Raaum, Erik Dean; Potter, Garrett Thomas; Ly, Tai Wei, 3,5-diaminopyrazole kinase inhibitors.
  7. Raaum, Erik Dean; Potter, Garrett Thomas; Ly, Tai Wei, 3,5-diaminopyrazole kinase inhibitors.
  8. Raaum, Erik Dean; Potter, Garrett Thomas; Ly, Tai Wei, 3,5-diaminopyrazole kinase inhibitors.
  9. Raaum, Erik Dean; Potter, Garrett Thomas; Ly, Tai Wei, 3,5-diaminopyrazole kinase inhibitors.
  10. Kyle, Donald J.; Tafesse, Laykea; Zhou, Xiaoming, 7,8-cyclicmorphinan analogs.
  11. Tafesse, Laykea, 7-beta-alkyl analogs of orvinols.
  12. Habib, Walid A.; Hamed, Ehab; Vega Zepeda, Manuel A., Abuse resistant drug formulation.
  13. Habib, Walid A.; Hamed, Ehab; Vega Zepeda, Manuel A., Abuse resistant drug formulation.
  14. Habib, Walid A.; Hamed, Ehab; Vega Zepeda, Manuel A., Abuse resistant drug formulation.
  15. Habib, Walid; Hamed, Ehab; Moe, Derek; Kraling, Carrie; Hillman, Lisa, Abuse resistant drug formulation.
  16. Rekhi, Gurvinder S.; Sidwell, Richard, Abuse resistant pharmaceutical compositions.
  17. Rekhi, Gurvinder Singh; Sidwell, Richard, Abuse resistant pharmaceutical compositions.
  18. Rekhi, Gurvinder Singh; Sidwell, Richard, Abuse resistant pharmaceutical compositions.
  19. Rekhi, Gurvinder Singh; Sidwell, Richard, Abuse resistant pharmaceutical compositions.
  20. Rekhi, Gurvinder Singh; Sidwell, Richard, Abuse resistant pharmaceutical compositions.
  21. Hirsh, Jane; Fleming, Alison; Rariy, Roman; Klibanov, Alexander, Abuse-deterrent drug formulations.
  22. Matthews, Frank; Boehm, Garth; Tang, Lijuan; Liang, Alfred, Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist.
  23. Matthews, Frank; Boehm, Garth; Tang, Lijuan; Liang, Alfred, Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist.
  24. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  25. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  26. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  27. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  28. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  29. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  30. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  31. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  32. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  33. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  34. Caruso, Frank S.; Kao, Huai-Hung, Abuse-resistant controlled-release opioid dosage form.
  35. Mehta, Atul M., Abuse-resistant oral dosage forms and method of use thereof.
  36. Mehta, Atul M., Abuse-resistant oral dosage forms and method of use thereof.
  37. Mehta, Atul M., Abuse-resistant oral dosage forms and method of use thereof.
  38. Huntley, C. Frederick M.; Kataisto, Erik Wayne; Reisch, Helge Alfred; Sharma, Archana, Acetate salt of buprenorphine and methods for preparing buprenorphine.
  39. Coulter, Bruce Lee, Actinic radiation reactor.
  40. Tian, Feng; Dang, Qun; Prasad, G. Sridhar; Li, Wenyu; Bookser, Brett C.; Raffaele, Nicholas Brian; Erion, Mark D., Activators of glucokinase.
  41. Tian, Feng; Dang, Qun; Prasad, G. Sridhar; Li, Wenyu; Bookser, Brett C.; Raffaele, Nicholas Brian; Erion, Mark D., Activators of glucokinase.
  42. Tian, Feng; Dang, Qun; Prasad, G. Sridhar; Li, Wenyu; Bookser, Brett C.; Raffaele, Nicholas Brian; Erion, Mark D., Activators of glucokinase.
  43. Tian, Feng; Dang, Qun; Prasad, G. Sridhar; Li, Wenyu; Bookser, Brett C.; Raffaele, Nicholas Brian; Erion, Mark D., Activators of glucokinase.
  44. Hostetler, Karl Y.; Beadle, James R.; Valiaeva, Nadejda, Acyclic nucleoside phosphonate diesters.
  45. Hostetler, Karl Y.; Beadle, James R.; Valiaeva, Nadejda, Acyclic nucleoside phosphonate diesters.
  46. Hamed, Ehab, Alcohol-resistant metoprolol-containing extended-release oral dosage forms.
  47. Cociorva, Oana; Li, Bei; Szardenings, Anna Katrin; Fukuda, Yasumichi; Nomura, Masahiro; Seto, Shigeki; Yumoto, Kazuhiro; Okada, Kyoko; Nakamura, Ayako, Aminoquinolones as GSK-3 inhibitors.
  48. Gomez-Galeno, Jorge E.; Reddy, K. Raja; van Poelje, Paul D.; Lemus, Robert Huerta; Nguyen, Thanh Huu; Grote, Matthew P.; Dang, Qun; Hecker, Scott J.; Mali, Venkat Reddy; Chen, Mingwei; Sun, Zhili; Boyer, Serge Henri; Li, Haiqing; Craigo, William, Antagonists of the glucagon receptor.
  49. Gomez-Galeno, Jorge E.; Reddy, Raja K.; van Poelje, Paul D.; Lemus, Robert Huerta; Nguyen, Thanh Huu; Grote, Matthew P.; Dang, Qun; Hecker, Scott J.; Mali, Venkat Reddy; Chen, Mingwei; Sun, Zhili; Boyer, Serge Henri; Li, Haiqing; Craigo, William, Antagonists of the glucagon receptor.
  50. Gomez-Galeno, Jorge E.; Reddy, Raja K.; van Poelje, Paul D.; Lemus, Robert Huerta; Nguyen, Thanh Huu; Grote, Matthew P.; Dang, Qun; Hecker, Scott J.; Mali, Venkat Reddy; Chen, Mingwei; Sun, Zhili; Boyer, Serge Henri; Li, Haiqing; Craigo, William, Antagonists of the glucagon receptor.
  51. Gomez-Galeno, Jorge E.; Reddy, Raja K.; van Poelje, Paul D.; Lemus, Robert Huerta; Nguyen, Thanh Huu; Grote, Matthew P.; Dang, Qun; Hecker, Scott J.; Mali, Venkat Reddy; Chen, Mingwei; Sun, Zhili; Boyer, Serge Henri; Li, Haiqing; Craigo, William, Antagonists of the glucagon receptor.
  52. Banovetz,John P.; Jacobs,Jeffry L., Anti-microbial agent delivery system.
  53. Cathers, Brian E.; Correa, Matthew Daniel; Hansen, Joshua; Lopez-Girona, Antonia; Khalil, Ehab M.; MacBeth, Kyle; Man, Hon-Wah; Muller, George W.; Pourdehnad, Michael; Raheja, Raj, Antiproliferative compounds and methods of use thereof.
  54. Cathers, Brian E.; Correa, Matthew Daniel; Hansen, Joshua; Lopez-Girona, Antonia; Khalil, Ehab M.; MacBeth, Kyle; Man, Hon-Wah; Muller, George W.; Pourdehnad, Michael; Raheja, Raj, Antiproliferative compounds and methods of use thereof.
  55. Hansen, Joshua; Correa, Matthew Daniel; Raheja, Raj; Lopez-Girona, Antonia; Man, Hon-Wah; Muller, George W.; Khalil, Ehab M.; MacBeth, Kyle; Cathers, Brian E.; Pourdehnad, Michael, Antiproliferative compounds and methods of use thereof.
  56. Alexander, Matthew D.; Correa, Matthew D.; Hansen, Joshua; Raheja, Raj Kumar; Sapienza, John, Antiproliferative compounds, and their pharmaceutical compositions and uses.
  57. Alexander, Matthew D.; Correa, Matthew D.; Hansen, Joshua; Raheja, Raj Kumar; Sapienza, John, Antiproliferative compounds, and their pharmaceutical compositions and uses.
  58. Lipkin, W. Ian; Hornig, Mady; Williams, Brent L., Autism-associated biomarkers and uses thereof.
  59. Cushman, Mark S.; Kiselev, Evgeny A.; Morrell, Andrew E.; Pommier, Yves George, Azaindenoisoquinoline topoisomerase I inhibitors.
  60. Tafesse, Laykea; Tsuno, Naoki; Zhou, Xiaoming, Azetidine-substituted quinoxalines as opioid receptor like-1 modulators.
  61. Liu, Gang, Azolyl urea compounds and methods of use thereof.
  62. Yong, Zhee Min Jimmy; Stibitz, David; Coulter, Bruce Lee; Hoosier, Michael Scott, Baffle plates for an ultraviolet reactor.
  63. Powers, Jay P.; Degraffenreid, Michael; Julian, Lisa; Kaizerman, Jacob; McMinn, Dustin; Rew, Yosup; Sun, Daqing; Yan, Xuelei; Wang, Zhulun; De Turiso, Felix Gonzalez Lopez, Benzamide derivatives and uses related thereto.
  64. Powers, Jay P.; Rew, Yosup; Yan, Xuelei, Benzamide derivatives and uses related thereto.
  65. Holladay, Mark W.; Liu, Gang; Rowbottom, Martin W., Biaryl acetamide compounds and methods of use thereof.
  66. Tafesse, Laykea, Bicycloheteroaryl compounds and their use as TRPV1 ligands.
  67. Ho,Chi Tang; Bai,Naisheng; Dong,Zigang; Bode,Ann M.; Dushenkov,Slavik, Bioactive compounds and methods of uses thereof.
  68. Ballatore, Carlo; Castellino, Angelo J; Smith, III, Amos B; Desharnais, Joel; Sun, Chengzao; Aspland, Simon E, C-10 carbamates of taxanes.
  69. Ghosh, Arun K.; Mitsuya, Hiroaki; Kalapala, Venkateswararao; Li, Jianfeng, CCR5 antagonists for treating HIV.
  70. Remenar,Jules; MacPhee,Michael; Peterson,Matthew Lynn; Morissette,Sherry Lynn; Almarsson,Orn, CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods.
  71. Zhang, Jian; Armer, Thomas A., Cabergoline derivatives.
  72. Martin, Roy, Calcium hypochlorite of reduced reactivity.
  73. Thakurta, Anjan; Gandhi, Anita; Waldman, Michelle F.; Chopra, Rajesh; Amatangelo, Michael; Bjorklund, Chad, Cereblon isoforms and their use as biomarkers for therapeutic treatment.
  74. Baron, Alain D.; Brown, Martin R.; Jones, Christopher R. G.; Fineman, Mark S., Chemosensory receptor ligand-based therapies.
  75. Baron, Alain; Brown, Martin R.; Jones, Christopher R. G., Chemosensory receptor ligand-based therapies.
  76. Baron, Alain; Brown, Martin R.; Jones, Christopher R. J., Chemosensory receptor ligand-based therapies.
  77. Schwitter, Urs; Bliss, Fritz; Kammerer, Michael; Tixeront, Florence, Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same.
  78. Li, Jian-Xin; Carlin, Brian A. C., Coating process to produce controlled release coatings.
  79. Von Coburg, Yvonne; Reimer, Karen; Oksche, Alexander; Holzer, Peter, Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation.
  80. Maneval, Daniel C.; Shepard, H. Michael; Thompson, Curtis B., Combination therapy with an anti-hyaluronan agent and therapeutic agent.
  81. Maneval, Daniel C.; Shepard, H. Michael; Thompson, Curtis B., Combination therapy with an anti-hyaluronan agent and therapeutic agent.
  82. Chamberlain, Philip; Cathers, Brian E.; Lopez-Girona, Antonia, Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases.
  83. Deftereos, Spyros; Persidis, Andreas, Compositions and methods for treating mitochondrial diseases.
  84. Wise, David, Compositions and methods for treating pelvic pain and other conditions.
  85. Jerussi, Thomas P.; Senanayake, Chrisantha H.; Fang, Qun K., Compositions comprising sibutramine metabolites in combination with phosphodiesterase inhibitors.
  86. Thanos, Christopher D.; Wang, Lin; Shepard, H. Michael, Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same.
  87. Yum, Su Il; Chao, Wendy; Su, Huey-Ching; Fu, Roger; Zamloot, Michael S.; Bratin, Karl; Shanker, Ravi M., Compositions with a rheological modifier to reduce dissolution variability.
  88. Yum, Su Il; Chao, Wendy; Su, Huey-Ching; Fu, Roger; Zamloot, Michael S.; Bratin, Karl; Shanker, Ravi M., Compositions with a rheological modifier to reduce dissolution variability.
  89. Hanania, Taleen G.; Heffernan, Michele L. R.; Jones, Philip Glyn; Xie, Linghong, Compounds and compositions and uses thereof.
  90. Sudhakar, Anantha, Compounds and methods for treatment of cancer.
  91. Surleraux, Dominique; Gosselin, Gilles, Compounds and pharmaceutical compositions for the treatment of viral infections.
  92. Brown, Kevin C.; Goehring, R. Richard; Baba, Yoshiyasu; Tsuno, Naoki, Compounds comprising heterocyclic-substituted piperidine for treating pain.
  93. Chen, Shoujun; Jiang, Jun; Li, Hao; James, David A.; Chimmanamada, Dinesh; Borella, Christopher; Sun, Lijun; Xie, Yu; Holmqvist, Mats; Mahiou, Jerome; Xia, Zhiqiang, Compounds for inflammation and immune-related uses.
  94. Chen, Shoujun; Jiang, Jun; Li, Hao; James, David; Chimmanamada, Dinesh; Borella, Christopher; Sun, Lijun; Xie, Yu; Holmqvist, Mats; Mahiou, Jerome; Xia, Zhiqiang, Compounds for inflammation and immune-related uses.
  95. Sun, Lijun; Chen, Shoujun; Jiang, Jun; Xie, Yu; Yu, Chih-Yi, Compounds for inflammation and immune-related uses.
  96. Sun, Lijun; Chen, Shoujun; Jiang, Jun; Xie, Yu; Yu, Chih-Yi, Compounds for inflammation and immune-related uses.
  97. Sun, Lijun; Chen, Shoujun; Xia, Zhi-Qiang; Jiang, Jun; Xie, Yu; Zhang, Junyi, Compounds for inflammation and immune-related uses.
  98. Sun, Lijun; Chen, Shoujun; Xia, Zhi-Qiang; Jiang, Jun; Xie, Yu; Zhang, Junyi, Compounds for inflammation and immune-related uses.
  99. Ghosh, Arun K., Compounds for treatment of Alzheimer's disease.
  100. Chen, Shoujun; Zhang, Junyi; Jiang, Jun; Bohnert, Gary; Vo, Nha; Che, Qinglin; Xia, Zhiqiang; Sun, Lijun, Compounds inclunding substituted pyridines for inflammation and immune-related uses.
  101. Snow, Alan D; Nguyen, Beth; Castillo, Gerardo; Sanders, Virginia; Lake, Thomas; Larsen, Lesley; Weavers, Rex T; Lorimer, Stephen; Larsen, David; Coffen, David L; Coffen, legal representative, Charlotte, Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease.
  102. Snow, Alan D.; Nguyen, Beth P.; Castillo, Gerardo M.; Sanders, Virginia J.; Lake, Thomas P.; Larsen, Lesley; Weavers, Rex T.; Lorimer, Stephen D.; Larsen, David S.; Coffen, legal representative, Charlotte; Coffen, David L., Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease.
  103. Esposito, Luke A.; Hudson, F. Michael; Lake, Thomas; Cummings, Joel; Weigele, Manfred; Snow, Alan D.; Larsen, Lesley, Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies.
  104. Sanders, Virginia; Cummings, Joel; Snow, Alan D, Compounds, compositions and methods for the treatment of inflammatory diseases.
  105. Lindquist, Susan L.; Outeiro, Tiago; Labaudinière, Richard, Compounds, compositions and methods of inhibiting alpha-synuclein toxicity.
  106. Esposito, Luke A.; Hudson, F. Michael; Lake, Thomas; Cummings, Joel; Weigele, Manfred; Snow, Alan D., Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies.
  107. Frisbee, Steven, Controlled release dosage forms.
  108. Frisbee, Steven, Controlled release dosage forms.
  109. Zhou, Fang; Maes, Paul, Controlled release dosage forms.
  110. Asrar, Jawed; Essinger, Jr., James F., Controlled release formulations and methods for their production and use.
  111. Oshlack,Benjamin; Chasin,Mark; Pedi, Jr.,Frank, Controlled release formulations coated with aqueous dispersions of acrylic polymers.
  112. Krishnamurthy, Thinnayam N.; Darke, Andrew, Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations.
  113. Krishnamurthy, Thinnayam N.; Darke, Andrew, Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations.
  114. Krishnamurthy, Thinnayam N.; Darke, Andrew, Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations.
  115. Krishnamurthy,Thinnayam N.; Darke,Andrew, Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations.
  116. Krishnamurthy,Thinnayam N.; Darke,Andrew, Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations.
  117. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone.
  118. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone.
  119. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone.
  120. Oshlack, Benjamin; Huang, Hua Pin; Masselink, John K.; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  121. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  122. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  123. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  124. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  125. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  126. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  127. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  128. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  129. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  130. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  131. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  132. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred, Controlled release hydrocodone formulations.
  133. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  134. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  135. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  136. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K.; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  137. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K; Tonelli, Alfred, Controlled release hydrocodone formulations.
  138. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred, Controlled release hydrocodone formulations.
  139. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred, Controlled release hydrocodone formulations.
  140. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  141. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  142. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  143. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  144. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  145. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  146. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred P., Controlled release hydrocodone formulations.
  147. Sriwongjanya Mongkol ; Weng Timothy ; Chou Joseph ; Chen Chih-Ming, Controlled release oral dosage form.
  148. Chen, Ming J.; Hui, Ho-Wah; Shen, Xiaole, Controlled release oral dosage forms of poorly soluble drugs and uses thereof.
  149. Miller,Ronald Brown; Malkowska,Sandra Therese Antoinette; Wimmer,Walter; Hahn,Udo; Leslie,Stewart Thomas; Smith,Kevin John; Winkler,Horst; Prater,Derek Allan, Controlled release tramadol tramadol formulation.
  150. Nara Eiji,JPX ; Akiyama Yohko,JPX ; Nakamura Kenji,JPX, Controlled-release composition.
  151. Lenaerts, Vincent; Ouadji-Njiki, Patricia Laure; Bacon, Johnatan; Ouzerourou, Rachid; Gervais, Sonia; Rahmouni, Miloud; Smith, Damon, Controlled-release compositions.
  152. Goldenheim, Paul D.; Sackler, Richard S.; Krishnamurthy, Thinnayam N.; Darke, Andrew; Oshlack, Benjamin, Controlled/modified release oral methylphenidate formulations.
  153. Goldenheim,Paul D.; Sackler,Richard S.; Krishnamurthy,Thinnayam N.; Darke,Andrew; Oshlaci,Benjamin, Controlled/modified release oral methylphenidate formulations.
  154. Remenar,Julius; MacPhee,Michael; Peterson,Matthew; Morissette,Sherry; Almarsson,Orn, Crystalline forms of conazoles and methods of making and using the same.
  155. Li, Bei; Szardenings, Anna Katrin, Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors.
  156. Tsuno, Naoki; Ueno, Tatsuhiko; Zhou, Xiaoming, Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators.
  157. Pettit, George R.; Tan, Rui; Pettit, Robin K., Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth.
  158. Mehta Atul M. ; Zeitlin Andrew L. ; Dariani Maghsoud M., Delivery of multiple doses of medications.
  159. Mehta, Atul M.; Zeitlin, Andrew L.; Dariani, Maghsoud M., Delivery of multiple doses of medications.
  160. Mehta,Atul M.; Zeitlin,Andrew L.; Dariani,Maghsoud M., Delivery of multiple doses of medications.
  161. Robinson, Joseph R.; McGinity, James W., Delivery system for omeprazole and its salts.
  162. Ruppert, Klaus; Renz, Karl-Heinz; Vogt, Sebastian, Dental materials equipped with active anti-plaque substance(s).
  163. Marom, Ehud; Rubnov, Shai, Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof.
  164. Thomas P. Jerussi ; Chrisantha H. Senanayake, Derivatives of (-)-venlafaxine and methods of preparing and using the same.
  165. Jerussi, Thomas P.; Senanayake, Chrisantha H.; Bhongle, Nandkumar N., Derivatives of venlafaxine and methods of preparing and using the same.
  166. Nuovo, Gerard; Nivar, Virginia, Diagnosis and treatment of viral diseases.
  167. Nuovo, Gerard; Nivar, Virginia, Diagnosis and treatment of viral diseases.
  168. Shin, Hyeon-Cheol; Hwang, Hyejeong; Park, Kwang Yong; Kim, Seong Ho; Lee, Haengwoo, Eckol derivatives, methods of synthesis and uses thereof.
  169. Huang, Haiyong Hugh, Encased tamper resistant controlled release dosage forms.
  170. Huang, Haiyong Hugh, Encased tamper resistant controlled release dosage forms.
  171. Huang, Haiyong Hugh, Encased tamper resistant controlled release dosage forms.
  172. Huang, Haiyong Hugh, Encased tamper resistant controlled release dosage forms.
  173. Huang, Haiyong Hugh, Encased tamper resistant controlled release dosage forms.
  174. Huang, Haiyong Hugh, Encased tamper resistant controlled release dosage forms.
  175. Martin,Roy, Enhanced air and water purification using continuous breakpoint halogenation with free oxygen radicals.
  176. Martin,Roy, Enhanced air and water purification using continuous breakpoint halogenation with free oxygen radicals.
  177. Armer, Thomas; McKinley, Geoff; Borland, Scott; Guzman, Miguel; Szabolcs, Ármin; Gerencser, János, Ergoline compounds and uses thereof.
  178. Armer, Thomas; McKinley, Geoff; Borland, Scott; Guzman, Miguel; Szabolcs, Ármin; Gerencser, János, Ergoline compounds and uses thereof.
  179. Armer, Thomas; McKinley, Geoff; Borland, Scott; Guzman, Miguel; Szabolcs, Ármin; Gerencser, János, Ergoline compounds and uses thereof.
  180. Armer, Thomas; McKinley, Geoff; Borland, Scott; Guzman, Miguel; Szabolcs, Ármin; Gerencser, János, Ergoline compounds and uses thereof.
  181. Nebuloni, Marino; Colombo, Patrizia, Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride.
  182. Nebuloni, Marino; Colombo, Patrizia, Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride.
  183. Nebuloni, Marino; Colombo, Patrizia, Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride.
  184. Wei, Ge; Selvam, Krishnasamy Panneer; Bookbinder, Louis; Frost, Gregory I., Extended soluble PH20 polypeptides and uses thereof.
  185. Murthy, Yerramilli V. S. N.; Vattakunnel, Felix, Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds.
  186. Amselem, Shimon, Flumazenil complexes, compositions comprising same and uses thereof.
  187. Cook, Robert O.; Zhang, Jian; Armer, Thomas A., Fluoroergoline analogs.
  188. Cook, Robert O.; Zhang, Jian; Armer, Thomas A., Fluoroergoline analogs.
  189. Cook, Robert O.; Zhang, Jian; Armer, Thomas A., Fluoroergoline analogs.
  190. Cook, Robert O.; Zhang, Jian; Armer, Thomas A., Fluoroergoline analogs.
  191. Cook, Robert O.; Zhang, Jian; Armer, Thomas A., Fluoroergoline analogs.
  192. Cook, Robert O.; Zhang, Jian; Armer, Thomas A., Fluoroergoline analogs.
  193. Tafesse, Laykea, Formula (IA″) compounds comprising (piperidin-4-yl)pyridine or (1,2,3,6-tetrahydropyridin-4-4yl) as TRPV1 antagonists.
  194. Martin, Roy, Free radical generator and method.
  195. Martin,Roy, Free radical generator and method.
  196. Gomez-Galeno, Jorge E.; Hecker, Scott J.; Dang, Qun; Reddy, Mali Venkat; Sun, Zhili; Grote, Matthew P.; Nguyen, Thanh Huu; Lemus, Robert Huerta; Li, Haiqing, Glucagon antagonists.
  197. Gomez-Galeno, Jorge E.; Hecker, Scott J.; Dang, Qun; Reddy, Mali Venkat; Sun, Zhili; Grote, Matthew P.; Nguyen, Thanh Huu; Lemus, Robert Huerta; Li, Haiqing, Glucagon antagonists.
  198. Gomez-Galeno, Jorge E.; Hecker, Scott J.; Dang, Qun; Reddy, Mali Venkat; Sun, Zhili; Grote, Matthew P.; Nguyen, Thanh Huu; Lemus, Robert Huerta; Li, Haiqing, Glucagon antagonists.
  199. Zhi, Lin, Glucagon antagonists.
  200. Campbell, John Emmerson; Campbell, Una; Hanania, Taleen G.; Shao, Liming, Heteroaryl compounds and methods of use thereof.
  201. Kyle, Donald J.; Tafesse, Laykea, Heterocyclic TRPV1 receptor ligands.
  202. Fang, Qun Kevin; Campbell, Una; Spear, Kerry L., Heterocyclic compounds and methods of use thereof.
  203. Hadd, Michael J.; Hocker, Michael D.; Holladay, Mark W.; Liu, Gang; Rowbottom, Martin W.; Xu, Shimin, Heterocyclic compounds and methods of use thereof.
  204. Hadd, Michael J.; Hocker, Michael D.; Holladay, Mark W.; Liu, Gang; Rowbottom, Martin W.; Xu, Shimin, Heterocyclic compounds and methods of use thereof.
  205. Hadd, Michael J.; Hocker, Michael D.; Holladay, Mark W.; Liu, Gang; Rowbottom, Martin W.; Xu, Shimin, Heterocyclic compounds and methods of use thereof.
  206. Frost, Gregory I.; Kundu, Anirban; Bookbinder, Louis H., Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof.
  207. Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Hyaluronidase and factor VIII compositions.
  208. Shepard, H. Michael; Li, Xiaoming; Thompson, Curtis, Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods.
  209. Danagher, Helen Kathleen; Hayes, Geoffrey Gerard; Heun, Gerhard Josef; Mohammad, Hassan; Walden, Malcolm; Whitehouse, Jonathon Oliver, Immediate release pharmaceutical compositions comprising oxycodone and naloxone.
  210. Danagher, Helen Kathleen; Hayes, Geoffrey Gerard; Heun, Gerhard Josef; Mohammad, Hassan; Walden, Malcolm; Whitehouse, Jonathon Oliver, Immediate release pharmaceutical compositions comprising oxycodone and naloxone.
  211. Muller,George W.; Shire,Mary, Immunotherapeutic agents.
  212. Ghosh, Arun K., Inhibitors of BACE1 and methods for treating Alzheimer's disease.
  213. Castro, Alfredo C.; Peluso, Stephane; Snyder, Daniel A.; Tibbitts, Thomas T., Inhibitors of monoacylglycerol lipase and methods of their use.
  214. Zhang, Jian; Cook, Robert O., Iso-ergoline derivatives.
  215. Zhang, Jian; Cook, Robert O., Iso-ergoline derivatives.
  216. Zhang, Jian; Cook, Robert O., Iso-ergoline derivatives.
  217. Armer, Thomas; McKinley, Geoff; Borland, Scott; Guzman, Miguel, Isoergoline compounds and uses thereof.
  218. Armer, Thomas; McKinley, Geoff; Borland, Scott; Guzman, Miguel, Isoergoline compounds and uses thereof.
  219. Armer, Thomas; McKinley, Geoff; Borland, Scott; Guzman, Miguel, Isoergoline compounds and uses thereof.
  220. Ly, Tai Wei; Potter, Garrett Thomas, Isotopically enriched arylsulfonamide CCR3 antagonists.
  221. Ly, Tai Wei; Potter, Garrett Thomas, Isotopically enriched arylsulfonamide CCR3 antagonists.
  222. Man, Hon-Wah; Cameron, Louise Michelle; Frank, Anthony Joseph, Isotopologues of isoindole derivatives.
  223. Abraham, Sunny; Chao, Qi; Hadd, Michael J.; Holladay, Mark W.; Liu, Gang; Setti, Eduardo, JAK kinase modulating compounds and methods of use thereof.
  224. Abraham, Sunny; Chao, Qi; Hadd, Michael J.; Holladay, Mark W.; Liu, Gang; Setti, Eduardo, JAK kinase modulating compounds and methods of use thereof.
  225. Abraham, Sunny; Chao, Qi; Hadd, Michael J.; Holladay, Mark W.; Liu, Gang; Setti, Eduardo, JAK kinase modulating compounds and methods of use thereof.
  226. Newton, John Michael; Leong, Chuei Wuei, Low temperature coatings.
  227. Hostetler, Karl Y.; Beadle, James R., Lung-targeted drugs.
  228. Hostetler, Karl Y.; Beadle, James R., Lung-targeted drugs.
  229. Brögmann, Bianca; Muhlau, Silke; Spitzley, Christof, Matrix for sustained, invariant and independent release of active compounds.
  230. Brögmann, Bianca; Mühlah, Silke; Spitzley, Christof, Matrix for sustained, invariant and independent release of active compounds.
  231. Brögmann, Bianca; Mühlau, Silke; Spitzley, Christof, Matrix for sustained, invariant and independent release of active compounds.
  232. Sichel, Cosima, Method and arrangement for a water treatment.
  233. Paul D. Rubin ; Timothy J. Barberich, Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist.
  234. Leyendecker, Petra; Hopp, Michael; Drews, Axel, Method and device for the assessment of bowel function.
  235. Coulter, Bruce Lee, Method and system for providing ultrapure water.
  236. Coulter, Bruce Lee, Method and system for providing ultrapure water.
  237. Coulter, Bruce Lee, Method for measuring a concentration of a compound in a liquid stream.
  238. Kendrup, John; Fyhr, Peter, Method for producing a controlled-release preparation.
  239. Zeldis, Jerome B., Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide.
  240. Zeldis, Jerome B., Method for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with antibodies.
  241. Trovato, Joseph P., Method for treating periodontal disease.
  242. Dudley, Jr., Samuel C., Method of improving diastolic dysfunction.
  243. Coulter, Bruce Lee, Method of irradiating a liquid.
  244. Brown, Douglas S.; Smith, Jeffrey A., Method of manufacture air freshening article.
  245. Treston, Anthony; Shah, Jamshed H.; D'Amato, Robert J.; Hunsucker, Kimberly A.; Rougas, John; Conner, Barry P.; Pribdula, Victor; Swartz, Glenn M., Method of synthesis of 4-amino-thalidomide enantiomers.
  246. Zeldis,Jerome B., Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias.
  247. Zeldis,Jerome B., Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders.
  248. Thomas P. Jerussi ; Chrisantha H. Senanayake ; Qun K. Fang, Methods and compositions for the treatment and prevention of sexual dysfunction.
  249. Wood, Christopher B.; Smith, Stuart W., Methods and compositions for the treatment of autoimmune disorders using clofarabine.
  250. Estok, Thomas M.; Zaknoen, Sara L.; Mansfield, Robert K.; Lawhon, Tracy, Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders.
  251. Lederman, Seth; Harris, Herb, Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine.
  252. Ritter, Andrew J., Methods and compositions for treating lactose intolerance.
  253. Lederman, Seth; Harris, Herbert, Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine.
  254. Vargas Rincon, Ricardo Alberto; Reiz, Joseph, Methods and compositions particularly for treatment of attention deficit disorder.
  255. Vargas Rincon, Ricardo Alberto; Reiz, Joseph, Methods and compositions particularly for treatment of attention deficit disorder.
  256. Parkhideh, Daryoush, Methods and compositions that enhance bioavailability of coenzyme-Q10.
  257. Parkhideh,Daryoush, Methods and compositions that enhance bioavailability of coenzyme-Q10.
  258. Rubin, Paul D.; Barberich, Timothy J., Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists.
  259. Paul D. Rubin ; Timothy J. Barberich, Methods and compositions using (-) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists.
  260. Schafer, Peter H.; Gandhi, Anita; Capone, Lori, Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases.
  261. Palazzini,Ernesto; Gambaro,Giovanni, Methods and compositions using sulodexide for the treatment of diabetic nephropathy.
  262. Montagnier, Luc; Skorupka, Corinne; Raymond, Phillipe; Bottero, Philippe, Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders.
  263. Schafer, Peter H.; Chopra, Rajesh; Lopez-Girona, Antonia; Corral, Laura; Wang, Maria Yinglin; Jackson, Pilgrim, Methods for determining drug efficacy using cereblon-associated proteins.
  264. Bookbinder, Louis; Kundu, Anirban; Frost, Gregory I., Methods for reducing intraocular pressure by administering a soluble hyaluronidase glycoprotein (sHASEGP).
  265. Zeldis, Jerome B., Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide.
  266. Yarchoan, Robert; Zeldis, Jerome B.; Polizzotto, Mark N.; Davis, David A.; Sereti, Irini; Uldrick, Thomas S.; Whitby, Denise; Khetani, Vikram, Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers.
  267. Lopez-Girona, Antonia; Schafer, Peter H.; Gandhi, Anita; Mendy, Derek; Daniel, Thomas O., Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor.
  268. Lopez-Girona, Antonia; Schafer, Peter H.; Gandhi, Anita; Mendy, Derek; Daniel, Thomas O., Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor.
  269. Day, Robert, Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast.
  270. Gandhi, Anita; Dimartino, Jorge; Chopra, Rajesh, Methods for the treatment of locally advanced breast cancer.
  271. Day, Robert, Methods for the treatment of psoriatic arthritis using apremilast.
  272. Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP).
  273. Lundy, Kristin M., Methods for treating age-related behavioral disorders in companion animals.
  274. Zeldis, Jerome B., Methods for treating amyloidosis using 4-(amino)-2-(2,6-Dioxo(3-piperidyl))- isoindoline-1,3-dione.
  275. Zeldis, Jerome B., Methods for treating amyloidosis with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione.
  276. Rubin, Paul D.; Barberich, Timothy J., Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron.
  277. Rubin, Paul D.; Barberich, Timothy J., Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron.
  278. Rubin Paul D. ; Barberich Timothy J., Methods for treating apnea, apnea disorders, bulimia, and other disorders using optically pure (+) norcisapride.
  279. Rubin, Paul D.; Barberich, Timothy J., Methods for treating bulimia using optically pure (-) norcisapride.
  280. Zeldis, Jerome B., Methods for treating diffuse large B-cell lymphoma with 3-(4-amino-1-OXO-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with second active agents.
  281. Schafer, Peter H.; Shankar, Sai, Methods for treating diseases using isoindoline compounds.
  282. Bookbinder, Louis; Kundu, Anirban; Frost, Gregory I., Methods for treating edema by administering a Soluble Hyaluronidase Glycoprotein (sHASEGP).
  283. Paul D. Rubin ; Timothy J. Barberich, Methods for treating irritable bowel syndrome using optically pure (+) norcisapride.
  284. Rubin,Paul D.; Barberich,Timothy J., Methods for treating irritable bowel syndrome using optically pure (-) norcisapride.
  285. Pietronigro, Dennis; Ervin-Hayes, Annette; Zeldis, Jerome B., Methods for treating lymphomas in certain patient populations and screening patients for said therapy.
  286. Zeldis, Jerome B., Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroindol-2-yl)-piperidine-2,6-dione follow by autologous stem cell transplantation.
  287. Zeldis, Jerome B., Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor.
  288. Zeldis, Jerome B., Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione.
  289. Zeldis, Jerome B., Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione in combination with antibodies.
  290. Zeldis, Jerome B., Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione in combination with proteasome inhibitor.
  291. Zeldis, Jerome B., Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation.
  292. Zeldis, Jerome B., Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation.
  293. Zeldis, Jerome B., Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione.
  294. Zeldis, Jerome B., Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione.
  295. Zeldis, Jerome B., Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione.
  296. Zeldis, Jerome B., Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone.
  297. Zeldis, Jerome B., Methods for treating newly diagnosed multiple myeloma with 3-(4-amino-1-OXO-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with second active agents.
  298. Zeldis, Jerome B., Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent.
  299. Zeldis, Jerome B., Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent.
  300. Rubin, Paul D.; Barberich, Timothy J., Methods for treating sleep apnea and sleep induced apnea using optically pure (+) norcisapride.
  301. Zeldis,Jerome B., Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline.
  302. Zeldis,Jerome B., Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione.
  303. Zeldis,Jerome B., Methods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl) ethyl]-3-oxoisoindoline-4-yl}carboxamide.
  304. Zeldis, Jerome B., Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione.
  305. Zeldis, Jerome B., Methods for treatment of hepatocellular carcinoma using 3-(4-amino-1-OXO-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione.
  306. Zeldis, Jerome B., Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione.
  307. Zeldis, Jerome B., Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a proteasome inhibitor.
  308. Zeldis, Jerome B., Methods for treatment of multiple myeloma using cyclopropane carboxylic acid {2-[(is)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 h-isoindol-4-yl}-amide.
  309. Zeldis, Jerome B.; Faleck, Herbert; Manning, Donald C., Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline.
  310. McLean, Allan Joseph, Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria.
  311. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred, Methods of manufacturing oral dosage forms.
  312. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K; Tonelli, Alfred, Methods of manufacturing oral formulations.
  313. Senanayake, Chris Hugh; Han, Zhengxu; Krishnamurthy, Dhileepkumar; Pflum, Derek, Methods of preparing didesmethylsibutramine and other sibutramine derivatives.
  314. Senanayake, Chris Hugh; Han, Zhengxu; Krishnamurthy, Dhileepkumar; Pflum, Derek, Methods of preparing didesmethylsibutramine and other sibutramine derivatives.
  315. Krishnamurthy, Thinnayam N.; Darke, Andrew, Methods of preparing oral controlled release formulations.
  316. Guido, Debora; Huang, Haiyong Hugh, Methods of preparing tamper resistant pharmaceutical formulations.
  317. Sackler, Richard S., Methods of preparing tamper resistant solid oral dosage forms.
  318. Bray, Paul F.; Holinstat, Michael, Methods of prevention or treatment for pathologic thrombosis or inflammation.
  319. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John K; Tonelli, Alfred, Methods of providing analgesia.
  320. Oshlack, Benjamin; Huang, Hua-Pin; Masselink, John; Tonelli, Alfred, Methods of providing analgesia.
  321. Jerussi Thomas P. ; Senanayake Chrisantha H. ; Fang Qun K., Methods of treating and preventing attention deficit disorders.
  322. Jerussi, Thomas P; Senanayake, Chrisantha H; Bhongle, Nandkumar N., Methods of treating and preventing pain, anxiety, and incontinence using derivatives of (?)-venlafaxine.
  323. Krishnamurthy, Thinnayam N.; Darke, Andrew, Methods of treating attention deficit hyperactivity disorder.
  324. Krishnamurthy, Thinnayam N.; Darke, Andrew, Methods of treating attention deficit hyperactivity disorder.
  325. Gualberto, Antonio; Scholz, Catherine Rose, Methods of treating cancer with farnesyltransferase inhibitors.
  326. Gualberto, Antonio; Scholz, Catherine Rose, Methods of treating cancer with farnesyltransferase inhibitors.
  327. Rubin, Paul D.; Barberich, Timothy J., Methods of treating gastro-esophogeal reflux disease using (-) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists.
  328. Lee, Ronald D.; Vakily, Majid; Mulford, Darcy; Wu, Jing-Tao; Atkinson, Stuart, Methods of treating gastrointestinal disorders independent of the intake of food.
  329. Leibel, Rudolph L.; Watanabe, Kazuhisa; Chung, Wendy K.; Fischer, Stuart G.; Leduc, Charles; Watson, Elizabeth; Cremona, Maria Laura, Methods of treating metabolic disease.
  330. Thakurta, Anjan; Hussein, Mohamed; Jacques, Christian, Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies.
  331. Zeldis, Jerome B., Methods of treating myelodysplastic syndromes using lenalidomide.
  332. Zeldis, Jerome B., Methods of treating myelodysplastic syndromes using lenalidomide.
  333. Zeldis, Jerome B., Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine.
  334. Zeldis, Jerome B., Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine.
  335. Jerussi,Thomas P; Senanayake,Chrisantha H.; Fang,Qun K., Methods of treating or preventing erectile dysfunction.
  336. Senanayake, Chrisantha Hugh; Fang, Qun Kevin; Han, Zhengxu; Krishnamurthy, Dhileepkumar, Methods of treating or preventing neuropathic pain using sibutramine metabolites.
  337. Senanayake, Chrisantha Hugh; Fang, Qun Kevin; Han, Zhengxu; Krishnamurthy, Dhileepkumar, Methods of treating or preventing pain using sibutramine metabolites.
  338. Jerussi, Thomas P.; Senanayake, Chrisantha H.; Fang, Qun K., Methods of treating or preventing weight gain, obesity, and related disorders.
  339. Keller, Gilbert; Frost, Gregory I., Methods of treatment of cellulite.
  340. Keller, Gilbert; Frost, Gregory I., Methods of treatment of collagen-mediated diseases and conditions.
  341. Zeldis,Jerome B., Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes.
  342. Zeldis, Jerome B., Methods of using 4-(amino)-2-(2,6-dioxo(3-piperidly))-isoindoline-3-dione for the treatment of myelodysplastic syndromes.
  343. Zeldis,Jerome B., Methods of using N-{[2-(2,6-dioxo(3-piperidyl)-1,3-dioxoisoindolin-4-yl]methyl} cyclopropyl-carboxamide for the treatment and management of myelodysplastic syndromes.
  344. Jerussi, Thomas P.; Senanayake, Chrisantha H.; Bhongle, Nandkumar N., Methods of using derivatives of (−)-venlafaxine.
  345. Jerussi, Thomas P.; Senanayake, Chrisantha H.; Bhongle, Nandkumar N., Methods of using derivatives of (−)-venlafaxine.
  346. Thomas P. Jerussi ; Chrisantha H. Senanayake ; Qun K. Fang, Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction.
  347. Zeldis, Jerome B., Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of acute myelogenous leukemia.
  348. Zeldis, Jerome B., Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias.
  349. Zeldis, Jerome B., Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias.
  350. Zeldis, Jerome B., Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias.
  351. Zeldis, Jerome B., Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas.
  352. Zeldis, Jerome B., Methods using immunomodulatory compounds for treatment of certain leukemias.
  353. Wu, Libo; Zhang, Jian, Methysergide derivatives.
  354. John P. Banovetz ; Kent E. Nielsen CA; Kai Li, Microspheres as a delivery vehicle for bio-active agents useful in agricultural applications.
  355. Peterson, Matthew; Hickey, Magali Bourghol; Oliveira, Mark; Almarsson, Örn; Remenar, Julius, Mixed co-crystals and pharmaceutical compositions comprising the same.
  356. Seth, Pawan; Maes, Paul J., Modified release compositions of at least one form of tramadol.
  357. Seth, Pawan; Maes, Paul J., Modified release formulations of at least one form of tramadol.
  358. Kyle, Donald J.; Tafesse, Laykea, Monocyclic compounds and their use as TRPV1 ligands.
  359. Devane John G.,IEX ; Stark Paul,IEX ; Fanning Niall M. M.,IEX, Multiparticulate modified release composition.
  360. Devane, John G.; Stark, Paul; Fanning, Niall M. M., Multiparticulate modified release composition.
  361. Devane, John G.; Stark, Paul; Fanning, Niall M. M., Multiparticulate modified release composition.
  362. Devane, John G.; Stark, Paul; Fanning, Niall M. M.; Rekhi, Gurvinder Singh, Multiparticulate modified release composition.
  363. Hayes, Geoffrey Gerard; Martinelli, Vincenzo; Mohammad, Hassan; Tamber, Harjit; Walden, Malcolm; Whitelock, Steve, Multiparticulates.
  364. Taneja, Rajneesh; Vakilynejad, Majid, Multiple PPI dosage form.
  365. Taneja, Rajneesh; Vakilynejad, Majid, Multiple PPI dosage form.
  366. Taneja, Rajneesh; Vakilynejad, Majid, Multiple PPI dosage form.
  367. Kyle, Donald J., N-substituted hydromorphones and the use thereof.
  368. Devane, John G; Stark, Paul; Fanning, Niall M. N.; Rekhi, Gurvinder Singh; Jenkins, Scott A.; Liversidge, Gary, Nanoparticulate and controlled release compositions comprising cefditoren.
  369. Cook, Robert O.; Zhang, Jian; Armer, Thomas A., Neuromodulatory compounds.
  370. Wei, Ge; Selvam, Krishnasamy Panneer; Bookbinder, Louis; Frost, Gregory I., Neutral active soluble truncated PH20 polypeptides and uses thereof.
  371. Park, Jae Hyun; Tafesse, Laykea, Nitrogen containing morphinan derivatives and the use thereof.
  372. Madison,Edwin L.; Yeh,Jiunn Chern, Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon.
  373. Madison,Edwin L.; Ong,Edgar O., Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon.
  374. Madison,Edwin L.; Ong,Edgar O., Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon.
  375. Madison,Edwin L.; Yeh,Jiunn Chern, Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon.
  376. Madison, Edwin L.; Ong, Edgar O.; Yeh, Jiunn-Chern, Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon.
  377. Madison, Edwin L.; Ong, Edgar O.; Yeh, Jiunn-Chern, Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon.
  378. Madison,Edwin L.; Ong,Edgar O., Nucleic acids encoding endotheliases, endotheliases and uses thereof.
  379. Hostetler, Karl Y.; Beadle, James R.; Valiaeva, Nadejda, Nucleotide analogs.
  380. Breder, Christopher; Wright, Curtis; Oshlack, Benjamin, Opiod agonist formulations with releasable and sequestered antagonist.
  381. Kaiko,Robert F.; Colucci,Robert D., Opioid agonist / antagonist combinations.
  382. Breder, Christopher; Wright, Curtis; Oshlack, Benjamin, Opioid agonist formulations with releasable and sequestered antagonist.
  383. Breder, Christopher; Wright, Curtis; Oshlack, Benjamin, Opioid agonist formulations with releasable and sequestered antagonist.
  384. Breder, Christopher; Wright, Curtis; Oshlack, Benjamin, Opioid agonist formulations with releasable and sequestered antagonist.
  385. Kaiko, Robert F.; Colucci, Robert D., Opioid agonist/antagonist combinations.
  386. Kaiko, Robert F.; Colucci, Robert D., Opioid agonist/antagonist combinations.
  387. Kaiko, Robert F.; Colucci, Robert D., Opioid agonist/antagonist combinations.
  388. Kaiko, Robert F.; Colucci, Robert D., Opioid agonist/antagonist combinations.
  389. Kaiko, Robert F.; Colucci, Robert D., Opioid agonist/antagonist combinations.
  390. Kaiko, Robert F.; Colucci, Robert D., Opioid agonist/antagonist combinations.
  391. Kaiko,Robert F.; Colucci,Robert D., Opioid agonist/antagonist combinations.
  392. Wright, Curtis; Colucci, Robert; El-Tahtawy, Ahmed, Opioid dosage forms having dose proportional steady state Cave and AUC and less than dose proportional single dose Cmax.
  393. Wright, Curtis; Colucci, Robert; El-Tahtawy, Ahmed, Opioid dosage forms having dose proportional steady state Cave and AUC and less than dose proportional single dose Cmax.
  394. Youngman, Mark, Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans.
  395. Evenstad, Kenneth L.; Wertz, Christian F.; Jensen, James S.; O'Neill, Victoria Ann; Berge, Stephen M., Opioid-containing oral pharmaceutical compositions and methods.
  396. Evenstad, Kenneth L.; Wertz, Christian F.; Jensen, James S.; O'Neill, Victoria Ann; Berge, Stephen M., Opioid-containing oral pharmaceutical compositions and methods.
  397. Fleischer, Wolfgang; Reimer, Karen; Leyendecker, Petra, Opioids for the treatment of the chronic obstructive pulmonary disease (COPD).
  398. Wright, IV, Curtis; Carpanzano, Anthony E., Oral dosage form comprising a therapeutic agent and an adverse-effect agent.
  399. Wright, IV,Curtis; Carpanzano,Anthony E., Oral dosage form comprising a therapeutic agent and an adverse-effect agent.
  400. Chen, Ming J.; Hui, Ho-Wah; Lee, Thomas; Kurtulik, Paul; Surapaneni, Sekhar, Oral dosage forms of cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide.
  401. Yum, Su Il; Schoenhard, Grant; Tipton, Arthur J.; Gibson, John W.; Middleton, John C., Oral drug delivery system.
  402. Yum, Su Il; Schoenhard, Grant; Tipton, Arthur J.; Gibson, John W.; Middleton, John C., Oral drug delivery system.
  403. Yum, Su Il; Schoenhard, Grant; Tipton, Arthur J.; Gibson, John W.; Middleton, John C.; Fu, Roger; Zamloot, Michael S., Oral drug delivery system.
  404. Yum, Su Il; Chao, Wendy; Su, Huey-Ching; Fu, Roger; Zamloot, Michael, Oral pharamaceutical dosage forms.
  405. Scicinski, Jan J.; van Osdol, William W.; Su, Huey-Ching; Arenberg, Michael H.; Shah, Jaymin, Oral pharmaceutical dosage forms.
  406. Scicinski, Jan J.; van Osdol, William W.; Su, Huey-Ching; Arenberg, Michael H.; Shah, Jaymin, Oral pharmaceutical dosage forms.
  407. Talwar Naresh,INX ; Sen Himadri,INX ; Staniforth John N.,GBX, Orally administered controlled drug delivery system providing temporal and spatial control.
  408. Talwar, Naresh; Sen, Himadri; Staniforth, John N., Orally administered drug delivery system providing temporal and spatial control.
  409. Marra, Jeffrey Michael; Tsuno, Naoki; Ueno, Tatsuhiko; Zhou, Xiaoming, Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators.
  410. Kao, Haui-Hung; Baichwal, Anand R.; McCall, Troy; Lee, David, Oxymorphone controlled release formulations.
  411. Kao, Huai-Hung; Baichwal, Anand R.; McCall, Troy; Lee, David, Oxymorphone controlled release formulations.
  412. Wei, Ge; Shepard, H. Michael; Zhao, Qiping; Connor, Robert James, PH20 polypeptide variants, formulations and uses thereof.
  413. McMahon, Jennifer; Peterson, Matthew; Zaworotko, Michael J.; Shattock, Tanise; Bourghol Hickey, Magali, Pharmaceutical co-crystal compositions and related methods of use.
  414. Liang, Alfred; Matthews, Frank; Boehm, Garth; Tang, Lijuan; Johnson, Frank; Stauffer, Joseph, Pharmaceutical composition.
  415. Matthews, Frank; Boehm, Garth; Tang, Lijuan; Liang, Alfred, Pharmaceutical composition.
  416. Grenier, Pascal; Taillemite, Julien; Serreau, Severine; Nhamias, Alain, Pharmaceutical composition containing coated, floating particles.
  417. Handa, Hiroshi; Ando, Hideki; Itoh, Takumi; Hotta, Kentaro, Pharmaceutical composition containing core factor involved in proliferation and differentiation of central nervous cell.
  418. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical composition containing gelling agent.
  419. Bosse, Paul, Pharmaceutical compositions.
  420. Bosse, Paul, Pharmaceutical compositions.
  421. Bosse, Paul, Pharmaceutical compositions.
  422. Bosse, Paul, Pharmaceutical compositions.
  423. Bosse, Paul, Pharmaceutical compositions.
  424. Bosse, Paul; Ameling, John; Schachtel, Bernard; Takigiku, Ray, Pharmaceutical compositions.
  425. Bosse, Paul; Ameling, John; Schachtel, Bernard; Takigiku, Ray, Pharmaceutical compositions.
  426. Bosse, Paul; Ameling, John; Schachtel, Bernard; Takigiku, Ray, Pharmaceutical compositions.
  427. Bosse, Paul; Ameling, John; Schachtel, Bernard; Takigiku, Ray, Pharmaceutical compositions.
  428. Bosse, Paul; Ameling, John; Schachtel, Bernard; Takigiku, Ray, Pharmaceutical compositions.
  429. Bosse, Paul; Ameling, John; Schachtel, Bernard; Takigiku, Ray, Pharmaceutical compositions.
  430. Bosse, Paul; Ameling, John; Schachtel, Bernard; Takigiku, Ray, Pharmaceutical compositions.
  431. Bosse, Paul; Ameling, John; Schachtel, Bernard; Takigiku, Ray, Pharmaceutical compositions.
  432. Bosse, Paul; Ameling, John; Schachtel, Bernard; Takigiku, Ray, Pharmaceutical compositions.
  433. Matthews, Frank; Boehm, Garth; Tang, Lijuan; Liang, Alfred, Pharmaceutical compositions.
  434. Bosse, Paul; Ameling, John; Kozarek, William; Schachtel, Bernard; Higgins, John, Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates.
  435. Matthews, Frank; Boehm, Garth; Tang, Lijuan; Liang, Alfred, Pharmaceutical compositions for the deterrence and/or prevention of abuse.
  436. Bosse, Paul; Ameling, John; Schachtel, Bernard; Takigiku, Ray, Pharmaceutical compositions for treating or preventing pain.
  437. Bosse, Paul; Ameling, John; Schachtel, Bernard; Takigiku, Ray, Pharmaceutical compositions for treating or preventing pain.
  438. Bosse, Paul; Ameling, John; Schachtel, Bernard; Takigiku, Ray, Pharmaceutical compositions for treating or preventing pain.
  439. Bosse, Paul; Ameling, John; Schachtel, Bernard; Takigiku, Ray, Pharmaceutical compositions for treating or preventing pain.
  440. Tawa, Mark; Remenar, Julius; Peterson, Matthew L.; Almarsson, Örn; Guzman, Hector; Chen, Hongming; Oliveira, Mark, Pharmaceutical compositions with improved dissolution.
  441. Dittmar, Gregory Paul; Amante, Joseph Michael; Cronk, Tony Ryan; Newby, Daniel Gary, Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures.
  442. Dittmar, Gregory Paul; Amante, Joseph Michael; Cronk, Tony Ryan; Newby, Daniel Gary, Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures.
  443. Dittmar, Gregory Paul; Amante, Joseph Michael; Cronk, Tony Ryan; Newby, Daniel Gary, Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures.
  444. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  445. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  446. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  447. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  448. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  449. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  450. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  451. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  452. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  453. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  454. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  455. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  456. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  457. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  458. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  459. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  460. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  461. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  462. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  463. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  464. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  465. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  466. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  467. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  468. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  469. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  470. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  471. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  472. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  473. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  474. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  475. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  476. Wright, Curtis; Oshlack, Benjamin; Breder, Christopher, Pharmaceutical formulation containing gelling agent.
  477. Brögmann, Bianca; Mühlau, Silke; Spitzley, Christof, Pharmaceutical preparation containing oxycodone and naloxone.
  478. Brögmann, Bianca; Mühlau, Silke; Spitzley, Christof, Pharmaceutical preparation containing oxycodone and naloxone.
  479. Oshlack, Benjamin; Van Buskirk, Glenn; Chasin, Mark; Huang, Hua-Pin; Vashi, Vijay, Pharmaceutical product comprising a sequestered agent.
  480. Oshlack, Benjamin; Van Buskirk, Glenn; Chasin, Mark; Huang, Hua-Pin; Vashi, Vijay, Pharmaceutical products.
  481. Tawa, Mark; Almarsson, Örn; Remenar, Julius, Pharmaceutical propylene glycol solvate compositions.
  482. Tawa, Mark; Almarsson, Örn; Remenar, Julius, Pharmaceutical propylene glycol solvate compositions.
  483. Tawa, Mark; Almarsson, Örn; Remenar, Julius, Pharmaceutically acceptable propylene glycol solvate of naproxen.
  484. Ly, Tai Wei; Raaum, Erik Dean, Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors.
  485. Hostetler, Karl Y.; Beadle, James R.; Choo, Hyunah, Phosphono-pent-2-en-1-yl nucleosides and analogs.
  486. Tadesse, Dawit; Tafesse, Laykea; Zhou, Xiaoming, Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof.
  487. Zaveri, Nurulain; Meyer, Michael, Piperdinyl nociceptin receptor compounds.
  488. Jaworsky, Markian S.; Chen, Roger Shen-Chu; Muller, George W., Polymorphic forms of 3-(4-amino-1-oxo-1, 3 dihydro-isoindo1-2-yl)-piperidine-2,6-dione.
  489. Jaworsky, Markian S.; Chen, Roger Shen-Chu; Muller, George W., Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione.
  490. Jaworsky, Markian S.; Chen, Roger Shen-Chu; Muller, George W., Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione.
  491. Jaworsky, Markian S.; Chen, Roger Shen-Chu; Muller, George W., Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione.
  492. Jaworsky, Markian S.; Chen, Roger Shen-Chu; Muller, George W., Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione.
  493. Jaworsky, Markian S.; Chen, Roger Shen-Chu; Muller, George W., Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione.
  494. Jaworsky, Markian S.; Chen, Roger Shen-Chu; Muller, George W., Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione.
  495. Jaworsky, Markian S.; Chen, Roger Shen-Chu; Muller, George W., Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione.
  496. Jaworsky, Markian S.; Chen, Roger Shen-Chu; Muller, George W.; Saindane, Manohar T.; Cameron, Louise M., Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione.
  497. Jaworsky, Markian S.; Chen, Roger Shen-Chu; Muller, George W.; Saindane, Manohar T.; Cameron, Louise M., Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione.
  498. Jaworsky,Markian S.; Chen,Roger Shen Chu; Muller,George W., Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione.
  499. Jaworsky, Markian S.; Chen, Roger Shen-Chu; Muller, George W., Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione).
  500. Ritter, Andrew J.; Savaiano, Dennis; Barnes, David; Klaenhammer, Todd, Prebiotic formulations and methods of use.
  501. Ritter, Andrew J.; Savaiano, Dennis; Barnes, David; Klaenhammer, Todd, Prebiotic formulations and methods of use.
  502. Ritter, Andrew J.; Savaiano, Dennis; Barnes, David; Klaenhammer, Todd, Prebiotic formulations and methods of use.
  503. Ritter, Andrew J.; Savaiano, Dennis; Barnes, David; Klaenhammer, Todd, Prebiotic formulations and methods of use.
  504. Ritter, Andrew J.; Savaiano, Dennis; Barnes, David; Klaenhammer, Todd, Prebiotic formulations and methods of use.
  505. Ritter, Andrew J.; Savaiano, Dennis; Barnes, David; Klaenhammer, Todd, Prebiotic formulations and methods of use.
  506. Ritter, Andrew J.; Savaiano, Dennis; Barnes, David; Klaenhammer, Todd Robert, Prebiotic formulations and methods of use.
  507. Saim, Said; Fleming, Alison B.; Varanasi, Ravi K., Process of making stable abuse-deterrent oral formulations.
  508. Saim, Said; Fleming, Alison B.; Varanasi, Ravi K., Process of making stable abuse-deterrent oral formulations.
  509. Saim, Said; Fleming, Alison B.; Varanasi, Ravi K., Process of making stable abuse-deterrent oral formulations.
  510. Khetani,Vikram; Luo,Yalin; Ramaswamy,Sowmianarayanan, Processes and intermediates for resolving piperidyl acetamide stereoisomers.
  511. Ren, Pingda; Martin, Michael; Isbester, Paul; Lane, Benjamin S.; Kropp, Jason, Processes for preparing isoquinolinones and solid forms of isoquinolinones.
  512. Ren, Pingda; Martin, Michael; Isbester, Paul; Lane, Benjamin S.; Kropp, Jason, Processes for preparing isoquinolinones and solid forms of isoquinolinones.
  513. Ren, Pingda; Martin, Michael; Isbester, Paul; Lane, Benjamin S.; Kropp, Jason, Processes for preparing isoquinolinones and solid forms of isoquinolinones.
  514. Saindane, Manohar T.; Cameron, Louise M., Processes for preparing polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-YL))-piperidine-2,6-dione.
  515. Lockman, Jeffrey, Propellane-based compounds and the use thereof.
  516. Madison, Edwin L., Protease screening methods and proteases identified thereby.
  517. Madison, Edwin L., Protease screening methods and proteases identified thereby.
  518. Madison, Edwin L., Protease screening methods and proteases identified thereby.
  519. Daniels, David J.; Parney, Ian F.; Peterson, Timothy E., Pyrazole derivatives as inhibitors of STAT3.
  520. Daniels, David J.; Parney, Ian F.; Peterson, Timothy E., Pyrazole derivatives as inhibitors of STAT3.
  521. Kluge, Arthur F., Pyrazolopyrimidinone kinase inhibitor.
  522. Murthi, Krishna K.; Casaubon, Rebecca; Kluge, Arthur F.; Smith, Chase C.; Vogt, Joachim, Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors.
  523. Lockman, Jeffrey; Tafesse, Laykea; Youngman, Mark A., Pyridonemorphinan analogs and biological activity on opioid receptors.
  524. Tafesse, Laykea, Pyridonemorphinan analogs and biological activity on opioid receptors.
  525. Jiang, Jun; Xia, Zhi-Qiang; Zhang, Junyi; Bohnert, Gary; Chen, Shoujun; Xie, Yu, Pyridylphenyl compounds for inflammation and immune-related uses.
  526. Hadd, Michael J.; Holladay, Mark W.; Rowbottom, Martin, Quinazoline compounds and methods of use thereof.
  527. Ghosh, Arun K., Quinazoline inhibitors of BACE 1 and methods of using.
  528. Abraham, Sunny; Bhagwat, Shripad S.; Campbell, Brian T.; Chao, Qi; Faraoni, Raffaella; Holladay, Mark W.; Lai, Andiliy G.; Rowbottom, Martin W.; Setti, Eduardo; Sprankle, Kelly G., RAF kinase modulator compounds and methods of use thereof.
  529. Abraham, Sunny; Bhagwat, Shripad S.; Campbell, Brian T.; Chao, Qi; Faraoni, Raffaella; Holladay, Mark W.; Lai, Andiliy G.; Rowbottom, Martin W.; Setti, Eduardo; Sprankle, Kelly G., RAF kinase modulator compounds and methods of use thereof.
  530. Abraham, Sunny; Bhagwat, Shripad S.; Campbell, Brian T.; Chao, Qi; Faraoni, Raffaella; Holladay, Mark W.; Lai, Andiliy G.; Rowbottom, Martin W.; Setti, Eduardo; Sprankle, Kelly G., RAF kinase modulator compounds and methods of use thereof.
  531. Abraham, Sunny; Bhagwat, Shripad S.; Campbell, Brian T.; Chao, Qi; Faraoni, Raffaella; Holladay, Mark W.; Lai, Andiliy G.; Rowbottom, Martin W.; Setti, Eduardo; Sprankle, Kelly G., RAF kinase modulator compounds and methods of use thereof.
  532. Abraham, Sunny; Bhagwat, Shripad S.; Campbell, Brian T.; Chao, Qi; Faraoni, Raffaella; Holladay, Mark W.; Lai, Andiliy G.; Rowbottom, Martin W.; Setti, Eduardo; Sprankle, Kelly G., RAF kinase modulator compounds and methods of use thereof.
  533. Mann, Joseph John; Kumar, J. S. Dileep, Radiolabeled compounds and uses thereof.
  534. Marom, Ehud; Rubnov, Shai, Random pentapolymer for treatment of autoimmune diseases.
  535. Brown, Douglas S.; Smith, Jeffrey A., Replaceable restroom urinal assemblies, including urinal screens.
  536. Chrisantha Hugh Senanayake ; Qun Kevin Fang ; Zhengxu Han ; Dhileepkumar Krishnamurthy, Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain.
  537. Breder, Christopher; Oshlack, Benjamin; Wright, Curtis, Sequestered antagonist formulations.
  538. Breder, Christopher; Oshlack, Benjamin; Wright, Curtis, Sequestered antagonist formulations.
  539. Boehm, Garth, Sequestering subunit and related compositions and methods.
  540. Boehm, Garth, Sequestering subunit and related compositions and methods.
  541. Boehm, Garth, Sequestering subunit and related compositions and methods.
  542. Shreder, Kevin; Hu, Yi; Fraser, Allister; Kohno, Yasushi; Kojima, Akihiko; Ishiyama, Junichi, Serine hydrolase inhibitors.
  543. Remenar,Julius; MacPhee,Michael; Peterson,Matthew Lynn; Tawa,Mark, Sertraline compositions.
  544. Pang, Yuan-Ping; Park, Jewn Giew; Tang, Jing; Millard, Charles B.; Schmidt, James J., Small-molecule botulinum toxin inhibitors.
  545. Pang, Yuan-Ping; Park, Jewn Giew; Wang, Shaohua; Vummenthala, Anuradha; Mishra, Rajesh K; Davis, Jon; Millard, Charles B.; Schmidt, James J., Small-molecule botulinum toxin inhibitors.
  546. Muller, George W.; Schafer, Peter H.; Man, Hon-Wah; Ge, Chuansheng; Xu, Jean, Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof.
  547. Muller, George W.; Schafer, Peter H.; Man, Hon-Wah; Ge, Chuansheng; Xu, Jean, Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof.
  548. Gross, Timothy David, Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith.
  549. Ren, Pingda; Martin, Michael; Isbester, Paul; Lane, Benjamin S.; Kropp, Jason, Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof.
  550. Fernandez, Paul F.; Ferretti, Antonio C.; Kothare, Mohit A.; Li, Ying; Man, Hon-Wah; Zhang, Weihong, Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses.
  551. Muller, George W.; Man, Hon-Wah; Cohen, Benjamin M.; Li, Ying; Xu, Jean; Leong, William W., Solid forms of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses.
  552. Muller, George W.; Man, Hon-Wah; Cohen, Benjamin M.; Li, Ying; Xu, Jean; Leong, William W., Solid forms of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses.
  553. Muller, George W.; Man, Hon-Wah; Cohen, Benjamin M.; Li, Ying; Xu, Jean; Leong, William W., Solid forms of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses.
  554. Muller, George; Man, Hon-Wah; Cohen, Benjamin M.; Li, Ying; Xu, Jean; Leong, William W., Solid forms of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses.
  555. Mansfield, Robert K.; Lawhon, Tracy; Dymock, Brian, Solid state forms of macrocyclic kinase inhibitors.
  556. Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases.
  557. Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases.
  558. Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases.
  559. Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases.
  560. Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases.
  561. Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases.
  562. Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases.
  563. Bookbinder, Louis; Kundu, Anirban; Frost, Gregory I., Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases.
  564. Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof.
  565. Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof.
  566. Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof.
  567. Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof.
  568. Bookbinder, Louis H.; Kundu, Anirbau; Frost, Gregory I., Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof.
  569. Bookbinder, Louis; Kundu, Anirban; Frost, Gregory I., Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof.
  570. Morissette,Sherry L.; Almarsson,Orn; Soukasene,Stephen, Solvates and polymorphs of ritonavir and methods of making and using the same.
  571. Cociorva, Oana; Fukuda, Yasumichi; Kohno, Yasushi; Li, Bei; Okada, Kyoko; Nakamura, Ayako; Nomura, Masahiro; Seto, Shigeki; Szardenings, Anna Katrin; Yumoto, Kazuhiro, Spirocyclic aminoquinolones as GSK-3 inhibitors.
  572. Cociorva, Oana; Fukuda, Yasumichi; Kohno, Yasushi; Li, Bei; Okada, Kyoko; Nakamura, Ayako; Nomura, Masahiro; Seto, Shigeki; Szardenings, Anna Katrin; Yumoto, Kazuhiro, Spirocyclic aminoquinolones as GSK-3 inhibitors.
  573. Goehring, R. Richard; Tafesse, Laykea; Youngman, Mark A., Spirocyclic morphinans and their use.
  574. Goehring, R. Richard; Tafesse, Laykea; Youngman, Mark A., Spirocyclic morphinans and their use.
  575. Guzman, Hector; Remenar, Julius; Almarsson, Orn, Statin pharmaceutical compositions and related methods of treatment.
  576. Miller Ronald Brown,CHX ; Leslie Stewart Thomas,GBX ; Malkowska Sandra Therese Antoinette,GBX ; Prater Derek Allan,GBX ; Knott Trevor John,GBX ; Heafield Joanne,GBX ; Challis Deborah,GBX, Substained release compositions and a method of preparing pharmaceutical compositions.
  577. Tanaka, Nobuyuki; Yamawaki, Kenji; Yao, Jiangchao; Yu, Jianming; Zhou, Xiaoming, Substituted benzimidazole-type piperidine compounds and uses thereof.
  578. Yamawaki, Kenji; Yao, Jiangchao; Yu, Jianming; Zhou, Xiaoming, Substituted benzimidazole-type piperidine compounds and uses thereof.
  579. Muller,George W.; Shire,Mary; Stirling,David I., Substituted imides.
  580. Zhang, Jian; Cook, Robert O.; Armer, Thomas A.; Kosarev, Sergey Alexandrovich; Xie, Dejian, Substituted indolo 4,3 FG quinolines useful for treating migraine.
  581. Kassick, Andrew; Lockman, Jeffrey; Tafesse, Laykea, Substituted morphinans and the use thereof.
  582. Kassick, Andrew; Lockman, Jeffrey; Tafesse, Laykea, Substituted morphinans and the use thereof.
  583. Tafesse, Laykea, Substituted pyridines useful for treating pain.
  584. Tsuno, Naoki; Whitehead, John W. F.; Yao, Jiangchao, Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators.
  585. Tsuno, Naoki; Yao, Jiangchao, Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators.
  586. Tsuno, Naoki; Yao, Jiangchao, Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators.
  587. Fuchino, Kouki; Goehring, R. Richard; Matsumura, Akira; Shao, Bin; Taoda, Yoshiyuki; Tsuno, Naoki; Whitehead, John William Frank; Yao, Jiangchao, Substituted-quinoxaline-type piperidine compounds and the uses thereof.
  588. Fuchino, Kouki; Goehring, R. Richard; Shao, Bin; Taoda, Yoshiyuki; Tsuno, Naoki; Whitehead, John William Frank; Yao, Jiangchao, Substituted-quinoxaline-type piperidine compounds and the uses thereof.
  589. Fuchino, Kouki; Goehring, R. Richard; Shao, Bin; Taoda, Yoshiyuki; Tsuno, Naoki; Whitehead, John William Frank; Yao, Jiangchao, Substituted-quinoxaline-type piperidine compounds and the uses thereof.
  590. Hadfield,Anthony Francis; Shah,Syed Muzafar; Provost,James Andrew, Succinate salt of O-desmethyl-venlafaxine.
  591. Gervais, Sonia; Smith, Damon; Contamin, Pauline; Ouzerourou, Rachid; Ma, My Linh, Sustained drug release composition.
  592. Gervais, Sonia; Smith, Damon; Contamin, Pauline; Ouzerourou, Rachid; Ma, My Linh, Sustained drug release composition.
  593. Gervais, Sonia; Smith, Damon; Contamin, Pauline; Ouzerourou, Rachid; Ma, My Linh, Sustained drug release compositions.
  594. Miller Ronald Brown,CHX ; Leslie Stewart Thomas,GBX ; Malkowska Sandra Therese Antoinette,GBX ; Prater Derek Allan,GBX ; Knott Trevor John,GBX ; Heafield Joanne,GBX ; Challis Deborah,GBX, Sustained release compositions and a method of preparing pharmaceutical compositions.
  595. Baichwal,Anand R.; Kao,Huai Hung; McCall,Troy W., Sustained release formulations of oxymorphone.
  596. Liang, Likan; Wang, Hua; Bhatt, Padmanabh P.; Vieira, Michael L., Sustained-release formulations of topiramate.
  597. Liang, Likan; Wang, Hua; Bhatt, Padmanabh P.; Vieira, Michael L., Sustained-release formulations of topiramate.
  598. Liang, Likan; Wang, Hua; Bhatt, Padmanabh P.; Vieira, Michael L., Sustained-release formulations of topiramate.
  599. Wertz, Christian F.; Jensen, James S.; O'Neill, Victoria Ann; Mahoney, Sean B.; Berge, Stephen M., Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug.
  600. Lenaerts, Vincent; Ouadji-Nijki, Patricia Laure; Bacon, Jonathan; Ouzérourou, Rachid; Gervais, Sonia; Rahmouni, Miloud; Smith, Damon, Sustained-release tramadol formulations with 24-hour efficacy.
  601. Wertz, Christian F.; Jensen, James S.; O'Neill, Victoria Ann; Mahoney, Sean B.; Berge, Stephen M., Sustained-released product comprising a combination of a non-opioid amine and a non-steroidal, anti-inflammatory drug.
  602. Treston, Anthony; Shah, Jamshed H.; D'Amato, Robert J.; Hunsucker, Kimberly A.; Rougas, John; Conner, Barry P.; Pribdula, Victor; Swartz, Glenn M., Synthesis of 4-amino-thalidomide enantiomers.
  603. Benoit,Didier; Safir,Adam; Chang,Han Ting; Charmot,Dominique; Okamoto,Kenji; Nishimura,Isao; Wang,Yong, Synthesis of photoresist polymers.
  604. Coulter, Bruce Lee, System and method for measuring and treating a liquid stream.
  605. Coulter, Bruce Lee, System for controlling introduction of a reducing agent to a liquid stream.
  606. Hummel, Michele; Kyle, Donald J.; Whiteside, Garth, Systems and methods for treating an opioid-induced adverse pharmacodynamic response.
  607. Hummel, Michele; Kyle, Donald J.; Whiteside, Garth, Systems and methods for treating an opioid-induced adverse pharmacodynamic response.
  608. Hummel, Michele; Kyle, Donald J.; Whiteside, Garth, Systems and methods for treating an opioid-induced adverse pharmacodynamic response.
  609. Hummel, Michele; Kyle, Donald J.; Whiteside, Garth, Systems and methods for treating an opioid-induced adverse pharmacodynamic response.
  610. Hummel, Michele; Kyle, Donald J.; Whiteside, Garth, Systems and methods for treating an opioid-induced adverse pharmacodynamic response.
  611. Hummel, Michele; Kyle, Donald J.; Whiteside, Garth, Systems and methods for treating an opioid-induced adverse pharmacodynamic response.
  612. Hummel, Michelle; Kyle, Donald J.; Whiteside, Garth, Systems and methods for treating an opioid-induced adverse pharmacodynamic response.
  613. Hummel, Michele; Kyle, Donald J.; Whiteside, Garth, Systems for treating an opioid-induced adverse pharmacodynamic response.
  614. Ando, Shigeru; Kurose, Noriyuki; Tafesse, Laykea, TRPV1 antagonists including dihydroxy substituent and uses thereof.
  615. Kurose, Noriyuki; Tafesse, Laykea, TRPV1 antagonists including dihydroxy substituent and uses thereof.
  616. Tafesse, Laykea, TRPV1 antagonists including dihydroxy substituent and uses thereof.
  617. Tafesse, Laykea, TRPV1 antagonists including dihydroxy substituent and uses thereof.
  618. Tafesse, Laykea, TRPV1 antagonists including dihydroxy substituent and uses thereof.
  619. Tafesse, Laykea, TRPV1 antagonists including dihydroxy substituent and uses thereof.
  620. Yu, Jianming, TRPV1 antagonists including dihydroxy substituent and uses thereof.
  621. Yu, Jianming, TRPV1 antagonists including dihydroxy substituent and uses thereof.
  622. Flath, Robert P.; Masselink, John K., Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same.
  623. Huang, Haiyong Hugh, Tamper resistant controlled release dosage forms.
  624. Huang, Haiyong Hugh, Tamper resistant controlled release dosage forms.
  625. McKenna, William H.; Mannion, Richard O.; O'Donnell, Edward P.; Huang, Haiyong H., Tamper resistant dosage forms.
  626. McKenna, William H.; Mannion, Richard O.; O'Donnell, Edward P.; Huang, Haiyong H., Tamper resistant dosage forms.
  627. Oshlack, Benjamin; Wright, Curtis; Haddox, J. David, Tamper resistant oral opioid agonist formulations.
  628. Guido, Debora; Huang, Haiyong Hugh, Tamper resistant pharmaceutical formulations.
  629. Guido, Debora; Huang, Haiyong Hugh, Tamper resistant pharmaceutical formulations.
  630. Guido, Debora; Huang, Haiyong Hugh, Tamper resistant pharmaceutical formulations.
  631. Guido, Debora; Huang, Haiyong Hugh, Tamper resistant pharmaceutical formulations.
  632. Shmeis, Rama Abu; Muley, Sheetal R.; Shen, Xiaohong; Zong, Zhixin, Tamper resistant pharmaceutical formulations.
  633. Shmeis, Rama Abu; Muley, Sheetal R.; Shen, Xiaohong; Zong, Zhixin, Tamper resistant pharmaceutical formulations.
  634. Sackler, Richard S., Tamper resistant solid oral dosage forms.
  635. Sackler, Richard S., Tamper resistant solid oral dosage forms.
  636. Oshlack, Benjamin; Wright, Curtis; Haddox, J. David, Tamper-resistant oral opioid agonist formulations.
  637. Oshlack, Benjamin; Wright, Curtis; Haddox, J. David, Tamper-resistant oral opioid agonist formulations.
  638. Oshlack, Benjamin; Wright, Curtis; Haddox, J. David, Tamper-resistant oral opioid agonist formulations.
  639. Oshlack, Benjamin; Wright, Curtis; Haddox, J. David, Tamper-resistant oral opioid agonist formulations.
  640. Oshlack, Benjamin; Wright, Curtis; Haddox, J. David, Tamper-resistant oral opioid agonist formulations.
  641. Oshlack, Benjamin; Wright, Curtis; Haddox, J. David, Tamper-resistant oral opioid agonist formulations.
  642. Oshlack, Benjamin; Wright, Curtis; Haddox, J. David, Tamper-resistant oral opioid agonist formulations.
  643. Oshlack, Benjamin; Wright, Curtis; Haddox, J. David, Tamper-resistant oral opioid agonist formulations.
  644. Oshlack, Benjamin; Wright, Curtis; Haddox, J. David, Tamper-resistant oral opioid agonist formulations.
  645. Oshlack, Benjamin; Wright, Curtis; Haddox, J.David, Tamper-resistant oral opioid agonist formulations.
  646. Oshlack, Benjamin; Wright, Curtis; Haddox, J.David, Tamper-resistant oral opioid agonist formulations.
  647. Oshlack, Benjamin; Wright, Curtis; Haddox, J.David, Tamper-resistant oral opioid agonist formulations.
  648. Rariy, Roman V.; Fleming, Alison; Hirsh, Jane C.; Saim, Said; Varanasi, Ravi K., Tamper-resistant pharmaceutical compositions of opioids and other drugs.
  649. Rariy, Roman; Fleming, Alison; Hirsh, Jane C.; Saim, Said; Varanasi, Ravi K., Tamper-resistant pharmaceutical compositions of opioids and other drugs.
  650. Mukherji, Gour; Goel, Sandhya; Arora, Vinod Kumar, Taste masked compositions.
  651. Appel, Leah Elizabeth; Friesen, Dwayne Thomas; LaChapelle, Edward Dennis; Konagurthu, Sanjay; Falk, Richard Frank; Reo, Joseph P., Taste-masked drugs in rupturing multiparticulates.
  652. Dorothy M. Morre ; D. James Morre ; Raymond Cooper ; Howard Sun ; Qing Ye CN, Tea catechin formulations and processes for making same.
  653. Dorothy M. Morre ; D. James Morre ; Raymond Cooper ; Michael N. Chang, Tea catechins in sustained release formulations as cancer specific proliferation inhibitors.
  654. Chen, Zhengming, Therapeutic agents useful for treating pain.
  655. Kyle, Donald J.; Sun, Qun, Therapeutic agents useful for treating pain.
  656. Kyle, Donald J.; Sun, Qun, Therapeutic agents useful for treating pain.
  657. Kyle, Donald J.; Sun, Qun; Tafesse, Laykea, Therapeutic agents useful for treating pain.
  658. Kyle, Donald J.; Sun, Qun; Tafesse, Laykea, Therapeutic agents useful for treating pain.
  659. Kyle, Donald J.; Sun, Qun; Tafesse, Laykea, Therapeutic agents useful for treating pain.
  660. Kyle, Donald J.; Sun, Qun; Zhou, Xiaoming, Therapeutic agents useful for treating pain.
  661. Kyle, Donald J.; Sun, Qun; Zhou, Xiaoming, Therapeutic agents useful for treating pain.
  662. Sun, Qun, Therapeutic agents useful for treating pain.
  663. Sun, Qun, Therapeutic agents useful for treating pain.
  664. Sun, Qun, Therapeutic agents useful for treating pain.
  665. Sun, Qun, Therapeutic agents useful for treating pain.
  666. Sun, Qun; Tafesse, Laykea, Therapeutic agents useful for treating pain.
  667. Sun, Qun; Tafesse, Laykea; Victory, Sam, Therapeutic agents useful for treating pain.
  668. Sun, Qun; Tafesse, Laykea; Victory, Sam, Therapeutic agents useful for treating pain.
  669. Sun, Qun; Tafesse, Laykea; Victory, Sam, Therapeutic agents useful for treating pain.
  670. Sun, Qun; Tafesse, Laykea; Victory, Sam, Therapeutic agents useful for treating pain.
  671. Sun, Qun; Tafesse, Laykea; Victory, Sam, Therapeutic agents useful for treating pain.
  672. Sun, Qun; Wen, Kate Xin, Therapeutic agents useful for treating pain.
  673. Sun, Qun; Wen, Kate Xin; Zhou, Xiaoming, Therapeutic agents useful for treating pain.
  674. Sun, Qun; Wen, Kate Xin; Zhou, Xiaoming, Therapeutic agents useful for treating pain.
  675. Sun, Qun; Wen, Xin, Therapeutic agents useful for treating pain.
  676. Sun, Qun; Wen, Xin, Therapeutic agents useful for treating pain.
  677. Sun, Qun; Wen, Xin, Therapeutic agents useful for treating pain.
  678. Vo, Nha Huu; Chen, Shoujun; Che, Qinglin; Xie, Yu, Thiazole and thiadiazole compounds for inflammation and immune-related uses.
  679. Califano, Andrea; Dalla-Favera, Riccardo, Tissue-specific MicroRNAs and compositions and uses thereof.
  680. Gervais, Sonia; Smith, Damon; Rahmouni, Miloud; Contamin, Pauline; Ouzerourou, Rachid; Ma, My Linh; Ferrada, Angela; Soulhi, Fouzia, Trazodone composition for once a day administration.
  681. Gervais, Sonia; Smith, Damon; Rahmouni, Miloud; Contamin, Pauline; Ouzerourou, Rachid; Ma, My Linh; Ferrada, Angela; Soulhi, Fouzia, Trazodone composition for once a day administration.
  682. Lovell, Mark; Lynn, Bert, Treatment of MCI and Alzheimer's disease.
  683. Chen,Zhengming; Victory,Sam, Triazaspiro compounds useful for treating or preventing pain.
  684. Chen,Zhengming; Victory,Sam, Triazaspiro compounds useful for treating or preventing pain.
  685. Gregor, Vlad Edward, Tyrosine kinase inhibitors.
  686. Gregor, Vlad Edward, Tyrosine kinase inhibitors.
  687. Gregor, Vlad Edward, Tyrosine kinase inhibitors.
  688. Gregor, Vlad Edward; Liu, Yahua; Anikin, Alexey Vyacheslavovich; Mikel, Charles Chamchoumis; McGrath, Douglas Eric; Vavilala, Goverdhan Reddy; Pickens, Jason Conrad; Kadushkin, Aleksander; Jiang, Luyong; Thiruvazhi, Mohan Santhanam; Zozulya, Sergey; Vairagoundar, Rajendran; Zhu, Tong; Chucholowski, Alexander; Yan, Zheng; Khasanov, Alisher, Tyrosine kinase inhibitors.
  689. Sitkiewitz, Steve Donald; Carmignani, Gary Michael; Fredrick, Lee William, Ultraviolet light activated oxidation process for the reduction of organic carbon in semiconductor process water.
  690. Brown, Douglas S.; Smith, Jeffrey A., Urinal screen.
  691. Brown, Douglas S.; Smith, Jeffrey A., Urinal screen.
  692. Brown, Douglas S.; Smith, Jeffrey A., Urinal screens.
  693. Koopmans, Guido; Hasse, Birgit; Mullner, Stefan, Use of leflunomide and malononitrilamides.
  694. McGee, Kevin; Zook, Scott; Carr, Andrew; Bonnaud, Thierry, Valbenazine salts and polymorphs thereof.
  695. Dennis, II, Richard; Rhodes, Jeffrey; Thomas, Edward; Marcukaitis, James, Water treatment control systems and methods of use.
  696. Dennis, II,Richard; Rhodes,Jeffrey; Thomas,Edward; Marcukaitis,James, Water treatment control systems and methods of use.
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로